Cheryl Czerlanis is an Oncology physician affiliated with Loyola University Chicago. OpenAlex indexes 31 publications with 369 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Highland Ave
Madison, WI 537920001
Telephone
608-265-1700Provider last certified this registry record 11 Dec 2024.
Clinical trials
- Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer
Sponsor: Loyola University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
34%Phenothiazine20%Prochlorperazine Maleate100%Part D≥14 patientsAtypical Antipsychotic14%Olanzapine100%Part D≥11 patientsMetabolism & gastrointestinal
27%Serotonin-3 Receptor Antagonist27%Ondansetron Hcl100%Part D≥21 patientsSensory organs
24%Corticosteroid24%Dexamethasone100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening
American Society of Clinical Oncology Educational Book
2025 - Multi-stakeholder, intentional outreach for improving representative recruitment in Pragmatica–Lung (SWOG S2302).
Journal of Clinical Oncology
2024 - Implementing a cognitive behavioral intervention for patients with head and neck cancer
Supportive Care in Cancer
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Marisa Luck
Loyola University Chicago
Amal Jubran, MD
Loyola University Chicago
Thomas Layden, MD
Loyola University Chicago
Elizabeth Mueller
Loyola University Chicago
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”